Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background & Aims: Optimizing treatment efficacy is still a critical part in advancing the treatment of breast cancer. Dietary interventions have drawn significant attention for their potential to increase tumor sensitivity, with a plethora of strategies evaluated both preclinically and clinically. The aim of this paper is to explore these strategies, ranging from entire dietary programs to specific supplements, for their potential to directly enhance tumor sensitivity and chemotherapy adherence.
Methods: PubMed, Scopus, Embase and Web of Science databases were searched up to September 2023. In this comprehensive review, preclinical and clinical research on dietary interventions used in conjunction with chemotherapy for breast cancer was examined and synthesized, to identify potential causal mechanisms.
Results: 42 studies in total were identified and synthesized, 32 pre-clinical and 8 clinical studies.
Conclusion: Although a topic of intense interest, the heterogeneity in approaches has resulted in a large but minimally impactful evidence base, further complicated by a limited understanding of the mechanisms at play. This review highlights the areas for further research to increase opportunities for nutritional-based interventions as adjuvant to chemotherapy for breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clnesp.2024.06.048 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
ASO Visual Abstract: SPARC Expression Induces COL1A1/COL3A1 Representing Aggressive Molecular Cancer-Associated Fibroblast Signatures and CSF1-Mediated Cancer Invasion in Colorectal Cancer.
Ann Surg Oncol
September 2025
Division of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Preoperative Radiation Boost in Early-Stage Breast Cancer: Effect on Re-excision and Complication Rates.
Ann Surg Oncol
September 2025
Department of General Surgery, Abdulkadir Yuksel State Hospital, Gaziantep, Turkey.
ASO Visual Abstract: The Metaplastic Conundrum: An NCDB analysis of Metaplastic Versus Triple-Negative Ductal Breast Cancer.
Ann Surg Oncol
September 2025
Cincinnati Research in Outcomes and Safety in Surgery (CROSS) Research Group, Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Oncologic Anthropology and the African Diaspora: Twenty-Year Anniversary Report, International Center for the Study of Breast Cancer Subtypes (ICSBCS).
Ann Surg Oncol
September 2025
Department of Surgery, Komfo Anoyke Teaching Hospital, Kumasi, Ghana.
The International Center for the Study of Breast Cancer Subtypes (ICSBCS) has played a vital role in defining and overcoming many inequities that exist in breast cancer treatment and outcome on a global basis through capacity-building programs that improve the management of breast cancer patients across the African diaspora. ICSBCS activities also fill critical gaps in disparities research related to the genetics of ancestry. Over the past 20 years, ICSBCS teams have spearheaded landmark studies documenting the relevance of genetic African ancestry to breast cancer risk, while also improving the quality of care delivered to patients in diverse communities.
View Article and Find Full Text PDFInter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer.
Mol Diagn Ther
September 2025
Division of Pathology, IEO, European Institute of Oncology IRCCS, Via G. Ripamonti 435, 20141, Milan, Italy.
Background And Objective: Sacituzumab govitecan, an anti-trophoblast cell surface antigen 2 (TROP2) antibody-drug conjugate, has been approved by both the US Food and Drug Administration and European Medicines Agency for patients with metastatic triple-negative breast cancer who have received two or more prior systemic therapies, including at least one of them for advanced disease. Although TROP2 evaluation is not required for patient selection, survival data from the ASCENT trial show improved response rates in patients with high TROP2 expression by immunohistochemistry. However, there is no standardized testing assay for these patients.
View Article and Find Full Text PDF